AMRI, in the process of consolidating its drug discovery services, is teaming up with life sciences giant PerkinElmer to accelerate a new biomedical hub in Buffalo, NY.
Eli Lilly inked a pair of deals with Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute to hit the gas on oncology R&D, aiming to shorten the development process for a slew of new medicines.
India's GVK BioSciences, marred by a data scandal, has signed an exclusive deal with Swedish drug developer Medivir, agreeing to handle the bulk of the biotech's chemistry work.
As regulators and payers place increasing importance on real-world data, CRO PPD is working to expand its reach in the field, joining forces with a division of insurance giant Anthem.
Kite Pharma, at work on therapies that use the immune system to fight cancer, paired up with Adimab to expand its R&D efforts.
Philips, Siemens score big hospital bundling contracts, highlighting demand for value-based healthcare
Enormous, multi-year hospital contracts that leverage the scale of Royal Philips are key to the new HealthTech focus for the company. The conglomerate expects that as hospital systems themselves continue to consolidate and its own healthcare offerings continue to expand, it will be able to secure more all-encompassing, large deals as these healthcare providers look to cut costs through bundling.
German pharma giant Bayer is uniting with researchers at Johns Hopkins University to ferret out new treatments for retinal diseases, signing a 5-year deal targeting early-stage R&D.
Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.
A mystery Chinese investor ventured $30 million on San Diego-based BioAtla, which is developing early stage biologics activated in selective microenvironments. In a release, BioAtla noted potential applications in monoclonal antibodies, bispecific antibodies, antibody drug conjugates, immune checkpoint inhibitors and CAR-T cells.
Illumina and Chinese genomics company Annoroad are joining forces to develop noninvasive prenatal screening tools based on next-generation sequencing technology, a potentially fruitful collaboration as Illumina looks to gain ground in emerging markets and strengthen its foothold in a saturated prenatal testing field.